Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Cancer Res ; 60(17): 4709-13, 2000 Sep 01.
Article in English | MEDLINE | ID: mdl-10987273

ABSTRACT

beta-Catenin is a multifunctional molecule with important roles in intercellular adhesion and signal transduction. We reported previously that beta-catenin is mutated in human prostate cancer. In this study, we investigated the role of beta-catenin mutations on androgen receptor (AR) signaling. beta-Catenin significantly enhanced androgen-stimulated transcriptional activation by the AR. beta-Catenin also increased AR transcriptional activation by androstenedione and estradiol and diminished the antagonism of bicalutamide. Coimmunoprecipitation of beta-catenin with AR from LNCaP prostate cancer cells showed that the two molecules are present in the same complex. The amount of beta-catenin in complex with AR was increased by androgen. These findings implicate beta-catenin in the regulation of AR function and support a role for beta-catenin mutations in the pathogenesis of prostate cancer.


Subject(s)
Cytoskeletal Proteins/physiology , Receptors, Androgen/physiology , Trans-Activators , Transcriptional Activation/physiology , Androgen Antagonists/pharmacology , Androgens/physiology , Cytoskeletal Proteins/genetics , Cytoskeletal Proteins/metabolism , Humans , Ligands , Male , Mutation , Prostatic Neoplasms/genetics , Prostatic Neoplasms/metabolism , Receptors, Androgen/genetics , Receptors, Androgen/metabolism , Substrate Specificity , Tumor Cells, Cultured , beta Catenin
2.
Cancer ; 83(6): 1231-6, 1998 Sep 15.
Article in English | MEDLINE | ID: mdl-9740090

ABSTRACT

BACKGROUND: Interleukin-2 (IL-2) is used in the treatment of solid tumors and hematologic malignancies. Sudden death is a rare complication of IL-2 treatment. METHODS: A patient with lymphoma underwent chemoradiotherapy myeloablation and autologous stem cell transplantation. The stem cells were cultured in IL-2 (6000 IU/mL) for 24 hours prior to infusion. After engraftment, treatment with IL-2 (1.8 x 10(6) IU/m2/day administered subcutaneously) was begun. After 4 days of treatment, the patient suddenly died. An autopsy was performed. RESULTS: Histologic examination of the myocardium revealed a diffuse, lymphocytic infiltrate with scattered, multinucleated giant cells and foci of myocardial degeneration consistent with giant cell myocarditis. The lymphocytes were predominantly CD4 positive T cells, and the majority of these cells stained with antibodies for perforin, suggesting an unusual cytolytic role for these lymphocytes. DNA end-labeling of myocardial tissue sections revealed numerous apoptotic myocytes within the lymphocytic infiltrate. CONCLUSIONS: To the authors' knowledge, this is the first report of giant cell myocarditis in association with high dose chemotherapy, transplantation, and IL-2 immunomodulation. The authors suggest that the cytokine imbalance produced by IL-2 may have initiated a preferential activation of T helper cells and an autoimmune phenomenon manifesting as giant cell myocarditis.


Subject(s)
Antineoplastic Agents/adverse effects , Bone Marrow Transplantation , Giant Cells/pathology , Hematopoietic Stem Cell Transplantation , Interleukin-2/adverse effects , Lymphoma, Follicular/therapy , Myocarditis/pathology , Antineoplastic Agents/therapeutic use , Apoptosis , Fatal Outcome , Female , Humans , Interleukin-2/therapeutic use , Middle Aged , Transplantation, Autologous
3.
Cancer Res ; 58(12): 2520-3, 1998 Jun 15.
Article in English | MEDLINE | ID: mdl-9635571

ABSTRACT

Beta-catenin plays essential roles in both intercellular adhesion and signal transduction. As a signaling molecule, beta-catenin supplies an activating domain to the T-cell factor/lymphoid enhancer-binding factor family of DNA-binding proteins and activates gene transcription. Posttranslational stabilization of beta-catenin, leading to elevated protein levels and constitutive gene activation, has been proposed as an important step in oncogenesis. Stabilization of beta-catenin can occur through mutation to highly conserved amino acids encoded in exon 3 of the beta-catenin gene (CTNNB1). To determine whether this pathway of malignant transformation is important in prostate cancer, we analyzed 104 prostate cancer tissue specimens, 4 prostate cancer cell lines, and 3 prostate tumor xenografts for activating mutations in exon 3 of CTNNB1. Mutations were detected in 5 of the 104 prostate cancer tissue samples. Four of the five mutations involved serine or threonine residues implicated in the degradation of beta-catenin. A fifth tumor had a mutation at codon 32, changing a highly conserved aspartic acid to a tyrosine. Mutational analysis of multiple regions from several tumor samples showed that the beta-catenin mutations were present focally and therefore may occur during tumor progression.


Subject(s)
Cytoskeletal Proteins/genetics , Neoplasm Proteins/genetics , Point Mutation/genetics , Prostatic Neoplasms/genetics , Trans-Activators , Exons/genetics , Humans , Male , Polymorphism, Single-Stranded Conformational , Prostatic Neoplasms/chemistry , beta Catenin
SELECTION OF CITATIONS
SEARCH DETAIL
...